Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer

Brachytherapy. 2023 May-Jun;22(3):317-324. doi: 10.1016/j.brachy.2022.12.005. Epub 2023 Jan 9.

Abstract

Purpose: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer.

Methods: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28...30 Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure. We compared overall survival (OS), disease-free survival (DFS), hospitalizations, and toxicity.

Results: There were 32 patients in the 3F group and 118 in the LF group, with a median follow up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was 3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade ...3 toxicity compared to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths.

Conclusions: Local control was excellent, with long term survival and toxicity similar between the groups. These findings support consideration of 3F.

Keywords: Cervical cancer; HDR brachytherapy; Hypofractionation.

MeSH terms

  • Brachytherapy* / methods
  • Clinical Protocols
  • Disease-Free Survival
  • Female
  • Humans
  • Progression-Free Survival
  • Radiotherapy Dosage
  • Uterine Cervical Neoplasms* / radiotherapy